FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286296056> ?p ?o ?g. }

• W4286296056 endingPage "12056" @default.
• W4286296056 startingPage "12056" @default.
• W4286296056 abstract "12056 Background: Emerging data support multiple benefits of RSM during chemotherapy to improve outcomes. These studies do not focus on older adults and do not include non-chemotherapy strategies. mPC represents a major burden in older men. Although both chemotherapy and androgen receptor axis-targeted therapies (ARATs) prolong survival, toxicities are substantial and increased in older men. Understanding the feasibility of RSM and key symptoms experienced by men with mPC on treatment is crucial to designing appropriate supportive care interventions. We aimed to assess RSM feasibility and understand key symptoms during treatment with chemotherapy or an ARAT among older men. Methods: Older adults aged 65+ starting chemotherapy, an ARAT, or Radium-223 for mPC were enrolled in a prospective observational multicentre study. Participants completed the Edmonton Symptom Assessment Scale (ESAS) on weekdays online or by phone. Weekly detailed questionnaires assessed mood, anxiety, fatigue, insomnia, and pain. Notifications were sent to the clinical oncology team with severe symptoms (ESAS 7 or higher). Study duration was the first treatment cycle (̃3-4 weeks). Feasibility data were analyzed descriptively. Linear mixed effects models examined symptoms over time and by cohort. Clinician responses were assessed descriptively. Results: A total of 90 men were included (mean age 76.5y, 48% ARAT, 38% chemotherapy, and 14% Radium-223, 42% frail by Vulnerable Elders Survey-13 cutoff of 3+). Approximately half the patients preferred phone-based RSM. Patients provided RSM responses in 1,874 of approximately 2,000 (94%) instances. In the combined cohort, the most common symptoms of moderate to severe intensity (ESAS 4 or higher) occurring at least once were poor well-being (66%), fatigue (62%), reduced appetite (56%), insomnia (54%), and pain (46%). Symptom patterns were similar between chemotherapy and ARAT groups. Moderate to severe symptoms were more common and lasted longer among frail than non-frail men. Symptoms tended to remain stable or improve over the course of 3-4 weeks of RSM. 89% of participants were satisfied or very satisfied with RSM, although daily reporting was reported by several as burdensome. 45% had severe symptoms from RSM leading to informing the oncology care team, 79% of whom were followed up by a nurse or physician, and 12% of treatments were modified. Conclusions: RSM is feasible, acceptable to older adults, and identifies clinically relevant symptoms, but accommodation needs to be made for phone and the optimal frequency of RSM needs to be established. Poor well-being, fatigue, reduced appetite, and insomnia occurred in over half of participants. Longer-term follow up will be important." @default.
• W4286296056 created "2022-07-21" @default.
• W4286296056 creator A5001659044 @default.
• W4286296056 creator A5006302277 @default.
• W4286296056 creator A5010011424 @default.
• W4286296056 creator A5012719520 @default.
• W4286296056 creator A5022267545 @default.
• W4286296056 creator A5036161954 @default.
• W4286296056 creator A5043875410 @default.
• W4286296056 creator A5045971699 @default.
• W4286296056 creator A5047993583 @default.
• W4286296056 creator A5048578488 @default.
• W4286296056 creator A5049964525 @default.
• W4286296056 creator A5051321514 @default.
• W4286296056 creator A5068330765 @default.
• W4286296056 creator A5076477372 @default.
• W4286296056 creator A5082815909 @default.
• W4286296056 creator A5088388062 @default.
• W4286296056 creator A5088466765 @default.
• W4286296056 date "2022-06-01" @default.
• W4286296056 modified "2023-09-28" @default.
• W4286296056 title "Remote symptom monitoring (RSM) during treatment for metastatic prostate cancer (mPC) in older men: Feasibility and efficacy." @default.
• W4286296056 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.12056" @default.
• W4286296056 hasPublicationYear "2022" @default.
• W4286296056 type Work @default.
• W4286296056 citedByCount "0" @default.
• W4286296056 crossrefType "journal-article" @default.
• W4286296056 hasAuthorship W4286296056A5001659044 @default.
• W4286296056 hasAuthorship W4286296056A5006302277 @default.
• W4286296056 hasAuthorship W4286296056A5010011424 @default.
• W4286296056 hasAuthorship W4286296056A5012719520 @default.
• W4286296056 hasAuthorship W4286296056A5022267545 @default.
• W4286296056 hasAuthorship W4286296056A5036161954 @default.
• W4286296056 hasAuthorship W4286296056A5043875410 @default.
• W4286296056 hasAuthorship W4286296056A5045971699 @default.
• W4286296056 hasAuthorship W4286296056A5047993583 @default.
• W4286296056 hasAuthorship W4286296056A5048578488 @default.
• W4286296056 hasAuthorship W4286296056A5049964525 @default.
• W4286296056 hasAuthorship W4286296056A5051321514 @default.
• W4286296056 hasAuthorship W4286296056A5068330765 @default.
• W4286296056 hasAuthorship W4286296056A5076477372 @default.
• W4286296056 hasAuthorship W4286296056A5082815909 @default.
• W4286296056 hasAuthorship W4286296056A5088388062 @default.
• W4286296056 hasAuthorship W4286296056A5088466765 @default.
• W4286296056 hasConcept C118552586 @default.
• W4286296056 hasConcept C121608353 @default.
• W4286296056 hasConcept C126322002 @default.
• W4286296056 hasConcept C159110408 @default.
• W4286296056 hasConcept C1862650 @default.
• W4286296056 hasConcept C188816634 @default.
• W4286296056 hasConcept C201903717 @default.
• W4286296056 hasConcept C27415008 @default.
• W4286296056 hasConcept C2779951463 @default.
• W4286296056 hasConcept C2780192828 @default.
• W4286296056 hasConcept C2780733359 @default.
• W4286296056 hasConcept C558461103 @default.
• W4286296056 hasConcept C71924100 @default.
• W4286296056 hasConcept C72563966 @default.
• W4286296056 hasConceptScore W4286296056C118552586 @default.
• W4286296056 hasConceptScore W4286296056C121608353 @default.
• W4286296056 hasConceptScore W4286296056C126322002 @default.
• W4286296056 hasConceptScore W4286296056C159110408 @default.
• W4286296056 hasConceptScore W4286296056C1862650 @default.
• W4286296056 hasConceptScore W4286296056C188816634 @default.
• W4286296056 hasConceptScore W4286296056C201903717 @default.
• W4286296056 hasConceptScore W4286296056C27415008 @default.
• W4286296056 hasConceptScore W4286296056C2779951463 @default.
• W4286296056 hasConceptScore W4286296056C2780192828 @default.
• W4286296056 hasConceptScore W4286296056C2780733359 @default.
• W4286296056 hasConceptScore W4286296056C558461103 @default.
• W4286296056 hasConceptScore W4286296056C71924100 @default.
• W4286296056 hasConceptScore W4286296056C72563966 @default.
• W4286296056 hasFunder F4320319921 @default.
• W4286296056 hasIssue "16_suppl" @default.
• W4286296056 hasLocation W42862960561 @default.
• W4286296056 hasOpenAccess W4286296056 @default.
• W4286296056 hasPrimaryLocation W42862960561 @default.
• W4286296056 hasRelatedWork W1574754333 @default.
• W4286296056 hasRelatedWork W1984684443 @default.
• W4286296056 hasRelatedWork W2104036120 @default.
• W4286296056 hasRelatedWork W2146295077 @default.
• W4286296056 hasRelatedWork W2169931607 @default.
• W4286296056 hasRelatedWork W2727005442 @default.
• W4286296056 hasRelatedWork W2962205323 @default.
• W4286296056 hasRelatedWork W3094095530 @default.
• W4286296056 hasRelatedWork W3098066378 @default.
• W4286296056 hasRelatedWork W4213392682 @default.
• W4286296056 hasVolume "40" @default.
• W4286296056 isParatext "false" @default.
• W4286296056 isRetracted "false" @default.
• W4286296056 workType "article" @default.